Patent ID: 11970544
Assignee: GENMAB A/S
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 12:
13. A method of producing a bispecific antibody that binds to both human 5T4 and human CD3, the method comprising the steps of:
(a) providing an antibody capable of binding to 5T4 by culturing the host cell of claim 11 under conditions allowing expression of the antibody capable of binding to 5T4, and purifying the antibody capable of binding to 5T4 from the culture medium;
(b) providing an antibody capable of binding to CD3 by culturing a host cell comprising:
(i) a nucleic acid construct encoding a heavy chain sequence of an antibody comprising an antigen-binding region capable of binding to CD3, wherein the heavy chain comprises a variable heavy chain (VH) region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 54, 55 and 67, respectively, and
(ii) a nucleic acid construct encoding a light chain sequence of an antibody comprising an antigen-binding region capable of binding to CD3, wherein the light chain comprises a variable light chain (VL) region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 58, the sequence GTN, and SEQ ID NO: 59, respectively;
under conditions allowing expression of the antibody capable of binding to CD3, and purifying the antibody capable of binding to CD3 from the culture medium;

(c) incubating the antibody capable of binding to 5T4 together with the antibody capable of binding to CD3 under reducing conditions sufficient to allow cysteines in the hinge region to undergo disulfide-bond isomerization, and
(d) obtaining the bispecific antibody.